KR102819951B1 - 아자벤즈이미다졸 화합물 및 의약 - Google Patents
아자벤즈이미다졸 화합물 및 의약 Download PDFInfo
- Publication number
- KR102819951B1 KR102819951B1 KR1020207035176A KR20207035176A KR102819951B1 KR 102819951 B1 KR102819951 B1 KR 102819951B1 KR 1020207035176 A KR1020207035176 A KR 1020207035176A KR 20207035176 A KR20207035176 A KR 20207035176A KR 102819951 B1 KR102819951 B1 KR 102819951B1
- Authority
- KR
- South Korea
- Prior art keywords
- methyl
- pyridin
- trifluoromethyl
- imidazo
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/396—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JPJP-P-2018-089867 | 2018-05-08 | ||
| JP2018089867 | 2018-05-08 | ||
| PCT/JP2019/018201 WO2019216294A1 (ja) | 2018-05-08 | 2019-05-07 | アザベンゾイミダゾール化合物及び医薬 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20210006437A KR20210006437A (ko) | 2021-01-18 |
| KR102819951B1 true KR102819951B1 (ko) | 2025-06-13 |
Family
ID=68467433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207035176A Active KR102819951B1 (ko) | 2018-05-08 | 2019-05-07 | 아자벤즈이미다졸 화합물 및 의약 |
Country Status (35)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3792260T (pt) | 2018-05-08 | 2024-10-02 | Nippon Shinyaku Co Ltd | Compostos de azabenzimidazol e produtos farmacêuticos |
| BR112022008457A2 (pt) * | 2019-11-13 | 2022-07-26 | Nippon Shinyaku Co Ltd | Agente terapêutico e agente profilático para distúrbios gastrointestinais funcionais e xerostomia |
| CA3161582A1 (en) | 2019-11-13 | 2021-05-20 | Nippon Shinyaku Co., Ltd. | Azabenzimidazole compound and medicine |
| CN118045050B (zh) * | 2023-11-16 | 2025-06-10 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 一种头颈部放疗患者适用的缓解口腔干燥的组合物及其制备方法 |
| WO2025153078A1 (zh) * | 2024-01-17 | 2025-07-24 | 盛睿泽华医药科技（苏州）有限公司 | 可溶性环氧水解酶抑制剂及其应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013545779A (ja) | 2010-12-17 | 2013-12-26 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 過剰増殖性障害の治療におけるｍｐｓ−１およびｔｋｋ阻害剤として使用するための６置換イミダゾピラジン |
| JP2016509048A (ja) | 2013-02-20 | 2016-03-24 | カンサー・セラピューティクス・シーアールシー・プロプライエタリー・リミテッドＣａｎｃｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｒｃ Ｐｔｙ Ｌｉｍｉｔｅｄ | アスパラギンメチル転移酵素の阻害剤としての２−（ヘテロ）アリールベンゾイミダゾール及びイミダゾピリジン誘導体 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5571819A (en) | 1994-11-22 | 1996-11-05 | Sabb; Annmarie L. | Imidazopyridines as muscarinic agents |
| NO2005012I1 (no) | 1994-12-28 | 2005-06-06 | Debio Rech Pharma Sa | Triptorelin og farmasoytisk akseptable salter derav |
| UA73543C2 (uk) | 1999-12-07 | 2005-08-15 | Тераванс, Інк. | Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором |
| JP2007528418A (ja) | 2004-03-11 | 2007-10-11 | セラヴァンス， インコーポレーテッド | ムスカリンレセプターアンタゴニストとしての有用なジフェニルメチル化合物 |
| TW200538095A (en) | 2004-03-11 | 2005-12-01 | Theravance Inc | Biphenyl compounds useful as muscarinic receptor antagonists |
| EP1734820A4 (en) | 2004-04-16 | 2008-01-23 | Neurogen Corp | Imidazopyrrazine, imidazopyridine, and imidazo-pyrimidine as CRF1 receptor ligands |
| EP2275095A3 (en) | 2005-08-26 | 2011-08-17 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| ES2274712B1 (es) * | 2005-10-06 | 2008-03-01 | Laboratorios Almirall S.A. | Nuevos derivados imidazopiridina. |
| JP5054770B2 (ja) | 2006-07-11 | 2012-10-24 | デウン ファーマシューティカル カンパニー リミテッド | 新規のビアリールベンゾイミダゾール誘導体及びこれを含む医薬組成物 |
| US8008307B2 (en) | 2006-08-08 | 2011-08-30 | Millennium Pharmaceuticals, Inc. | Heteroaryl compounds useful as inhibitors of E1 activating enzymes |
| GB0706168D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| WO2009092764A1 (en) * | 2008-01-24 | 2009-07-30 | Ucb Pharma, S.A. | Compounds comprising a cyclobutoxy group |
| PL2416761T3 (pl) | 2009-05-11 | 2015-07-31 | Ratiopharm Gmbh | Desfezoterodyna w postaci soli kwasu winowego |
| WO2011018894A1 (en) | 2009-08-10 | 2011-02-17 | Raqualia Pharma Inc. | Pyrrolopyrimidine derivatives as potassium channel modulators |
| JP5667934B2 (ja) * | 2010-06-28 | 2015-02-12 | 大日本住友製薬株式会社 | 新規２環性複素環化合物からなる医薬 |
| TWI541243B (zh) | 2010-09-10 | 2016-07-11 | 拜耳知識產權公司 | 經取代咪唑并嗒 |
| JP2013545776A (ja) * | 2010-12-17 | 2013-12-26 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 過剰増殖性障害の治療におけるｍｐｓ−１およびｔｋｋ阻害剤として使用するための６置換イミダゾピラジン |
| SG11201400102WA (en) | 2011-08-24 | 2014-03-28 | Millennium Pharm Inc | Inhibitors of nedd8-activating enzyme |
| JP2013237634A (ja) | 2012-05-14 | 2013-11-28 | Dainippon Sumitomo Pharma Co Ltd | 縮環イミダゾロン誘導体 |
| TWI647227B (zh) | 2013-02-28 | 2019-01-11 | 日商安斯泰來製藥股份有限公司 | ２－醯胺噻唑衍生物或其鹽 |
| US9951060B2 (en) | 2014-06-06 | 2018-04-24 | Astellas Pharma Inc. | 2-acylaminothiazole derivative or salt thereof |
| CN106573928B (zh) | 2014-08-26 | 2020-04-14 | 安斯泰来制药株式会社 | 2-氨基噻唑衍生物或其盐 |
| JP6680297B2 (ja) | 2015-04-28 | 2020-04-15 | アステラス製薬株式会社 | 経口投与用医薬組成物 |
| WO2018112840A1 (en) | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | 6, 5-fused heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor |
| US11136324B2 (en) | 2017-03-03 | 2021-10-05 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Substituted imidazoles as apoptosis signal regulating kinase 1 inhibitors |
| KR102735800B1 (ko) | 2017-12-21 | 2024-11-28 | 교린 세이야쿠 가부시키가이샤 | 야간빈뇨 치료제 |
| JPWO2019189766A1 (ja) | 2018-03-30 | 2021-04-08 | 持田製薬株式会社 | 新規ビアリールアミド誘導体 |
| PT3792260T (pt) | 2018-05-08 | 2024-10-02 | Nippon Shinyaku Co Ltd | Compostos de azabenzimidazol e produtos farmacêuticos |
| TW202012415A (zh) | 2018-05-08 | 2020-04-01 | 瑞典商阿斯特捷利康公司 | 化學化合物 |
| BR112022008457A2 (pt) | 2019-11-13 | 2022-07-26 | Nippon Shinyaku Co Ltd | Agente terapêutico e agente profilático para distúrbios gastrointestinais funcionais e xerostomia |
| CA3161582A1 (en) | 2019-11-13 | 2021-05-20 | Nippon Shinyaku Co., Ltd. | Azabenzimidazole compound and medicine |
-
2019
- 2019-05-07 PT PT198002867T patent/PT3792260T/pt unknown
- 2019-05-07 MX MX2020011855A patent/MX2020011855A/es unknown
- 2019-05-07 DK DK19800286.7T patent/DK3792260T3/da active
- 2019-05-07 LT LTEPPCT/JP2019/018201T patent/LT3792260T/lt unknown
- 2019-05-07 JP JP2020518289A patent/JP7235047B2/ja active Active
- 2019-05-07 MD MDE20210245T patent/MD3792260T2/ro active IP Right Revival
- 2019-05-07 HU HUE19800286A patent/HUE068695T2/hu unknown
- 2019-05-07 MY MYPI2020005795A patent/MY202833A/en unknown
- 2019-05-07 SM SM20240407T patent/SMT202400407T1/it unknown
- 2019-05-07 SG SG11202011003TA patent/SG11202011003TA/en unknown
- 2019-05-07 RS RS20241035A patent/RS65996B1/sr unknown
- 2019-05-07 UA UAA202007681A patent/UA126774C2/uk unknown
- 2019-05-07 PE PE2020001816A patent/PE20211384A1/es unknown
- 2019-05-07 HR HRP20241414TT patent/HRP20241414T1/hr unknown
- 2019-05-07 US US17/053,380 patent/US12319683B2/en active Active
- 2019-05-07 SI SI201930830T patent/SI3792260T1/sl unknown
- 2019-05-07 BR BR112020022662-9A patent/BR112020022662A2/pt unknown
- 2019-05-07 IL IL278517A patent/IL278517B2/en unknown
- 2019-05-07 CA CA3099655A patent/CA3099655A1/en active Pending
- 2019-05-07 WO PCT/JP2019/018201 patent/WO2019216294A1/ja not_active Ceased
- 2019-05-07 EP EP19800286.7A patent/EP3792260B1/en active Active
- 2019-05-07 FI FIEP19800286.7T patent/FI3792260T3/fi active
- 2019-05-07 PL PL19800286.7T patent/PL3792260T3/pl unknown
- 2019-05-07 AU AU2019265134A patent/AU2019265134B2/en active Active
- 2019-05-07 MA MA52587A patent/MA52587B1/fr unknown
- 2019-05-07 KR KR1020207035176A patent/KR102819951B1/ko active Active
- 2019-05-07 CN CN201980046177.6A patent/CN112368282B/zh active Active
- 2019-05-07 ES ES19800286T patent/ES2992256T3/es active Active
- 2019-05-08 TW TW108115846A patent/TWI868068B/zh active
-
2020
- 2020-11-05 SA SA520420487A patent/SA520420487B1/ar unknown
- 2020-11-05 CL CL2020002868A patent/CL2020002868A1/es unknown
- 2020-11-05 CO CONC2020/0013848A patent/CO2020013848A2/es unknown
- 2020-11-05 PH PH12020551873A patent/PH12020551873A1/en unknown
- 2020-11-17 ZA ZA2020/07164A patent/ZA202007164B/en unknown
- 2020-12-07 EC ECSENADI202078586A patent/ECSP20078586A/es unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013545779A (ja) | 2010-12-17 | 2013-12-26 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 過剰増殖性障害の治療におけるｍｐｓ−１およびｔｋｋ阻害剤として使用するための６置換イミダゾピラジン |
| JP2016509048A (ja) | 2013-02-20 | 2016-03-24 | カンサー・セラピューティクス・シーアールシー・プロプライエタリー・リミテッドＣａｎｃｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｒｃ Ｐｔｙ Ｌｉｍｉｔｅｄ | アスパラギンメチル転移酵素の阻害剤としての２−（ヘテロ）アリールベンゾイミダゾール及びイミダゾピリジン誘導体 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102819951B1 (ko) | 아자벤즈이미다졸 화합물 및 의약 | |
| US8822448B2 (en) | Pyrazoloquinoline compound | |
| KR102951288B1 (ko) | 아자벤즈이미다졸 화합물 및 의약 | |
| US20220324863A1 (en) | 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases | |
| RU2804485C2 (ru) | Азабензимидазольные соединения и фармкомпозиция | |
| HK40045733A (en) | Azabenzimidazole compounds and pharmaceutical | |
| HK40045733B (zh) | 氮杂苯并咪唑化合物和医药 | |
| HK40046611A (en) | Azabenzimidazole compounds and pharmaceutical | |
| HK40046611B (en) | Azabenzimidazole compounds and pharmaceutical | |
| HK40075503A (en) | Azabenzimidazole compound and medicine | |
| HK40076325A (en) | Azabenzimidazole compound and medicine | |
| EA039324B1 (ru) | 5,6–конденсированные бициклические соединения и композиции для лечения паразитарных заболеваний |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20201207 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20220321 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20240305 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20250313 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20250609 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20250610 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |